Phase II study of recombinant α-interferon in malignant melanoma

J. R. Neefe, S. S. Legha, Avi Markowitz, S. Salmon, F. Meyskens, J. Groopman, M. Campion, L. Evans

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Ninety-seven evaluable patients with measurable, advanced, malignant melanoma were treated with recombinant α interferon in a cooperative phase II efficacy trial, whose primary objective was to estimate the response rate. Interferon (rIFN α-2a, Roferon-A) was injected subcutaneously daily for 70 days. Dose was escalated in four steps from three million units to 36 million units over ten days. Eight patients responded objectively and six patients (6%) had a complete response. The median duration of complete response was 11 months. Patients achieving complete response had only cutaneous, nodal, or pulmonary disease; some had extensive prior therapy; some could tolerate no more than three million units per day. Few patients could tolerate the target dose of 36 million units daily for 70 days. Limiting toxicity was primarily fatigue. Interferon in tolerable doses is effective in a small subset of patients with melanoma. Comparison of published trials of dacarbazine and recombinant α interferon indicates the two drugs have similar activity.

Original languageEnglish
Pages (from-to)472-476
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number6
StatePublished - 1990
Externally publishedYes

Fingerprint

Interferons
Melanoma
Dacarbazine
Skin Diseases
Lung Diseases
Fatigue
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Neefe, J. R., Legha, S. S., Markowitz, A., Salmon, S., Meyskens, F., Groopman, J., ... Evans, L. (1990). Phase II study of recombinant α-interferon in malignant melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 13(6), 472-476.

Phase II study of recombinant α-interferon in malignant melanoma. / Neefe, J. R.; Legha, S. S.; Markowitz, Avi; Salmon, S.; Meyskens, F.; Groopman, J.; Campion, M.; Evans, L.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 13, No. 6, 1990, p. 472-476.

Research output: Contribution to journalArticle

Neefe, JR, Legha, SS, Markowitz, A, Salmon, S, Meyskens, F, Groopman, J, Campion, M & Evans, L 1990, 'Phase II study of recombinant α-interferon in malignant melanoma', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 13, no. 6, pp. 472-476.
Neefe JR, Legha SS, Markowitz A, Salmon S, Meyskens F, Groopman J et al. Phase II study of recombinant α-interferon in malignant melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials. 1990;13(6):472-476.
Neefe, J. R. ; Legha, S. S. ; Markowitz, Avi ; Salmon, S. ; Meyskens, F. ; Groopman, J. ; Campion, M. ; Evans, L. / Phase II study of recombinant α-interferon in malignant melanoma. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1990 ; Vol. 13, No. 6. pp. 472-476.
@article{faa9a70048d3492daefbad95e4ff70aa,
title = "Phase II study of recombinant α-interferon in malignant melanoma",
abstract = "Ninety-seven evaluable patients with measurable, advanced, malignant melanoma were treated with recombinant α interferon in a cooperative phase II efficacy trial, whose primary objective was to estimate the response rate. Interferon (rIFN α-2a, Roferon-A) was injected subcutaneously daily for 70 days. Dose was escalated in four steps from three million units to 36 million units over ten days. Eight patients responded objectively and six patients (6{\%}) had a complete response. The median duration of complete response was 11 months. Patients achieving complete response had only cutaneous, nodal, or pulmonary disease; some had extensive prior therapy; some could tolerate no more than three million units per day. Few patients could tolerate the target dose of 36 million units daily for 70 days. Limiting toxicity was primarily fatigue. Interferon in tolerable doses is effective in a small subset of patients with melanoma. Comparison of published trials of dacarbazine and recombinant α interferon indicates the two drugs have similar activity.",
author = "Neefe, {J. R.} and Legha, {S. S.} and Avi Markowitz and S. Salmon and F. Meyskens and J. Groopman and M. Campion and L. Evans",
year = "1990",
language = "English",
volume = "13",
pages = "472--476",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Phase II study of recombinant α-interferon in malignant melanoma

AU - Neefe, J. R.

AU - Legha, S. S.

AU - Markowitz, Avi

AU - Salmon, S.

AU - Meyskens, F.

AU - Groopman, J.

AU - Campion, M.

AU - Evans, L.

PY - 1990

Y1 - 1990

N2 - Ninety-seven evaluable patients with measurable, advanced, malignant melanoma were treated with recombinant α interferon in a cooperative phase II efficacy trial, whose primary objective was to estimate the response rate. Interferon (rIFN α-2a, Roferon-A) was injected subcutaneously daily for 70 days. Dose was escalated in four steps from three million units to 36 million units over ten days. Eight patients responded objectively and six patients (6%) had a complete response. The median duration of complete response was 11 months. Patients achieving complete response had only cutaneous, nodal, or pulmonary disease; some had extensive prior therapy; some could tolerate no more than three million units per day. Few patients could tolerate the target dose of 36 million units daily for 70 days. Limiting toxicity was primarily fatigue. Interferon in tolerable doses is effective in a small subset of patients with melanoma. Comparison of published trials of dacarbazine and recombinant α interferon indicates the two drugs have similar activity.

AB - Ninety-seven evaluable patients with measurable, advanced, malignant melanoma were treated with recombinant α interferon in a cooperative phase II efficacy trial, whose primary objective was to estimate the response rate. Interferon (rIFN α-2a, Roferon-A) was injected subcutaneously daily for 70 days. Dose was escalated in four steps from three million units to 36 million units over ten days. Eight patients responded objectively and six patients (6%) had a complete response. The median duration of complete response was 11 months. Patients achieving complete response had only cutaneous, nodal, or pulmonary disease; some had extensive prior therapy; some could tolerate no more than three million units per day. Few patients could tolerate the target dose of 36 million units daily for 70 days. Limiting toxicity was primarily fatigue. Interferon in tolerable doses is effective in a small subset of patients with melanoma. Comparison of published trials of dacarbazine and recombinant α interferon indicates the two drugs have similar activity.

UR - http://www.scopus.com/inward/record.url?scp=0025241447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025241447&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 472

EP - 476

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 6

ER -